Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study | Zendy

Pierre Delanaye | Zendy; Laurent Weekers | Zendy; Xavier Warling | Zendy; Martial Moonen | Zendy; Nicole Smelten | Zendy; Laurent Médart | Zendy; Jean-Marie Krzesinski | Zendy; Étienne Cavalier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study

Author(s) -

Pierre Delanaye,

Laurent Weekers,

Xavier Warling,

Martial Moonen,

Nicole Smelten,

Laurent Médart,

Jean-Marie Krzesinski,

Étienne Cavalier

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft001

Subject(s) - medicine , cholecalciferol , double blind , randomized controlled trial , hemodialysis , intensive care medicine , vitamin d and neurology , pathology , alternative medicine , placebo

The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether cholecalciferol therapy can increase serum 25-hydroxyvitamin D [25(OH)D] levels in haemodialysed patients and the safety implications of this therapy on certain biological parameters and vascular calcifications score.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research